From the Guidelines
Bactrim DS (trimethoprim-sulfamethoxazole) is generally considered better than ciprofloxacin for treating MRSA infections.
Key Points to Consider
- Bactrim DS is typically prescribed at a dose of 1-2 tablets (each containing 160mg trimethoprim and 800mg sulfamethoxazole) twice daily for 7-14 days, depending on infection severity 1.
- Ciprofloxacin has poor activity against MRSA and is not recommended as first-line therapy.
- Bactrim works by inhibiting bacterial folate synthesis at two different points, making it effective against many MRSA strains with resistance rates generally lower than those for fluoroquinolones like ciprofloxacin.
- When taking Bactrim DS, patients should maintain adequate hydration and be aware of potential side effects including rash, gastrointestinal upset, and rarely more serious reactions like Stevens-Johnson syndrome.
- For severe or invasive MRSA infections, intravenous antibiotics like vancomycin may be necessary instead of oral options.
- Treatment should always be guided by culture and sensitivity results whenever possible to ensure the most effective therapy.
Recommendations Based on Evidence
- The Infectious Diseases Society of America recommends Bactrim DS as an option for empirical coverage of CA-MRSA in outpatients with skin and soft tissue infections (SSTIs) 1, 2.
- Ciprofloxacin is not recommended due to its poor activity against MRSA.
- It is essential to consider the patient's clinical response and adjust the treatment duration accordingly, typically ranging from 5 to 14 days.
- For complicated SSTIs or severe infections, hospitalization and intravenous antibiotics may be necessary.
Important Considerations
- Patients should be monitored for potential side effects and resistance patterns.
- Local epidemiology and resistance patterns should guide the choice of antibiotic therapy.
- The use of rifampin as a single agent or as adjunctive therapy for the treatment of SSTI is not recommended 2.
From the Research
Comparison of Bactrim DS and Ciprofloxacin for MRSA Treatment
- Bactrim DS (trimethoprim-sulfamethoxazole) is considered a viable option for the treatment of MRSA infections, especially when the minimum inhibitory concentration (MIC) to vancomycin is 2 μg/mL or more 3.
- Ciprofloxacin, a quinolone antibiotic, has been studied as a potential treatment for MRSA infections, but its effectiveness is not as well-established as other options like vancomycin, daptomycin, or trimethoprim-sulfamethoxazole 4.
- A study comparing the clinical efficacy of trimethoprim-sulfamethoxazole (TMP/SMX) to linezolid and daptomycin found that TMP/SMX monotherapy had significantly better outcomes in terms of in-hospital and 90-day mortality, although this association was no longer significant in multivariate models 3.
- The use of trimethoprim-sulfamethoxazole (TMP/SMX) instead of linezolid or daptomycin could potentially reduce antibiotic costs, with an average cost savings of $2067.40 per patient 3.
- Current guidelines recommend considering alternative agents, such as daptomycin, ceftaroline, or trimethoprim-sulfamethoxazole, for the treatment of persistent MRSA bacteremia or bacteremia due to vancomycin-intermediate or vancomycin-resistant strains 5, 6.
- The choice of antibiotic for MRSA treatment should be based on individual patient factors, such as recent exposure, source control, and available synergy and clinical data 5.